Company intelligence / Profile preview

Broadwing Bio

South San Francisco or general Bay Area*, California, United Statesbroadwing.bio ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

The company is advancing robust antibody-based drugs directed at genetically validated targets for the treatment of vision loss. No clinical results have been published as of early 2025; programs are in preclinical development.

Therapeutic areas: Ophthalmology
Modalities: Antibody therapies (biologics)
Industry: Biotech

Drug pipeline

2 assets

MZE829

Phase 2

Indications: APOL1 kidney disease

1 more asset in the full pipeline.

Request access →

Partnerships

Maze TherapeuticsAlloy Therapeutics

Beyond the preview

Go deeper on Broadwing Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Broadwing Bio.

Explore the full profile